BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1934254)

  • 1. High-dose ara-C and etoposide in refractory or relapsing acute leukemia.
    Freund M; Link H; Diedrich H; LeBlanc S; Wilke HJ; Poliwoda H
    Cancer Chemother Pharmacol; 1991; 28(6):487-90. PubMed ID: 1934254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
    Vey N; Kantarjian H; Beran M; O'Brien S; Cortes J; Koller C; Estey E
    Invest New Drugs; 1999; 17(1):89-95. PubMed ID: 10555127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemia.
    Whitlock JA; Wells RJ; Hord JD; Janco RL; Greer JP; Gay JC; Edwards JR; McCurley TL; Lukens JN
    Leukemia; 1997 Feb; 11(2):185-9. PubMed ID: 9009078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone and standard dose cytosine arabinoside therapy in refractory or relapsed acute leukemia.
    Keskin A; Tombuloğlu M; Atamer MA; Büyükkeçeci F
    Acta Haematol; 1994; 92(1):14-7. PubMed ID: 7985476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
    Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose cytosine arabinoside and etoposide in the treatment of relapsed or refractory adult leukemia.
    Gryn J; Conroy J; Topolsky D; Crilley P; Kahn SB; Bulova S; Weiss J; Brodsky I
    Am J Clin Oncol; 1991 Feb; 14(1):52-4. PubMed ID: 1987740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide.
    Lee YG; Kwon JH; Kim I; Yoon SS; Lee JS; Park S
    Eur J Haematol; 2014 Jun; 92(6):478-84. PubMed ID: 24460733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
    Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F
    Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
    Jehn U; Heinemann V; Wilmanns W
    Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etoposide and cytosine arabinoside combination chemotherapy for refractory acute lymphocytic leukemia in childhood.
    Esumi N; Todo S; Arakawa S; Imashuku S
    J Clin Oncol; 1986 Jul; 4(7):1089-93. PubMed ID: 3459812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
    Yavuz S; Paydas S; Disel U; Sahin B
    Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsed or refractory adult acute lymphocytic leukemia.
    Freund M; Diedrich H; Ganser A; Gramatzki M; Heil G; Heyll A; Henke M; Hiddemann W; Haas R; Kuse R
    Cancer; 1992 Feb; 69(3):709-16. PubMed ID: 1730121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine and cytarabine as a sequential infusion regimen for treatment of adults with recurrent, refractory or poor prognosis acute leukemia.
    Vidarsson B; Abonour R; Williams EC; Woodson RD; Turman NJ; Kim K; Mosher DF; Wiersma SR; Longo WL
    Leuk Lymphoma; 2001 Apr; 41(3-4):321-31. PubMed ID: 11378544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia].
    Esumi N; Todo S; Arakawa S; Imashuku S
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):951-8. PubMed ID: 3963859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.
    Archimbaud E; Thomas X; Leblond V; Michallet M; Fenaux P; Cordonnier C; Dreyfus F; Troussard X; Jaubert J; Travade P
    J Clin Oncol; 1995 Jan; 13(1):11-8. PubMed ID: 7799010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.
    Robak T; Wrzesień-Kuś A; Lech-Marańda E; Kowal M; Dmoszyńska A
    Leuk Lymphoma; 2000 Sep; 39(1-2):121-9. PubMed ID: 10975390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen.
    Ho AD; Lipp T; Ehninger G; Illiger HJ; Meyer P; Freund M; Hunstein W
    J Clin Oncol; 1988 Feb; 6(2):213-7. PubMed ID: 3422260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idarubicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group.
    Carella AM; Carlier P; Pungolino E; Resegotti L; Liso V; Stasi R; Montillo M; Iacopino P; Mirto S; Pagano L
    Leukemia; 1993 Feb; 7(2):196-9. PubMed ID: 8426473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.